Anti Estrogen Steroid Letrozole Femara 112809-51-05 For Breast Cancer Treatment

Anti Estrogen Powder Letro Zole/Femara for Breast Cancer Treatment CAS: 112809-51-05

Description:

Femara is approved by the United States Food and Drug Administration (FDA) for the treatment of local or metastatic breast cancer that is hormone receptor positive or has an unknown receptor status in postmenopausal women.

Femara is intended for use only by women who are no longer of childbearing age. Possible candidates must have already ceased to menstruate. It is often used in patients who have already undergone other cancer treatments, such as radiation, chemotherapy, and used other cancer drugs, like tamoxifen. This nonsteroidal aromatase inhibitor may help prevent any remaining cancer cells from spreading.

Femara Usage:

Femara has a 2-4 day half-life, and it needs to be taken for up to 60 days to get a steady blood plasma level, using Femara such a low dose does happen to make it a very good economic choice compared with other aromatase inhibitors.

Femara Effects:

In one male test subject Femara was able to reduce estrogen levels to undetectable levels
Femara is able to raise in male subjects.
Femara has also been shown to delay the fusing of the growth plates in mice. When used in combination
with hormone, Femara has been shown effective in one adolescent boy with a short stature; Femara
has also been used to treat endometriosis a C17 α-alkylation which allows the hormone to survive f
irst-pass liver metabolism when ingested. 

Advantages:

Our products mainly are exported well into U.S. , Canada, Brazil, UK, Germany, Greece, Italy, Australia and many other areas. Our company gains high reputation among our old and new clients through the highest quality, best price, fast and safe delivery as well as the excellent customer service.